Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

BMC Psychiatry
Haya Ascher-SvanumJeff Swanson

Abstract

There is an ongoing debate over whether atypical antipsychotics are more effective than typical antipsychotics in the treatment of schizophrenia. This naturalistic study compares atypical and typical antipsychotics on time to all-cause medication discontinuation, a recognized index of medication effectiveness in the treatment of schizophrenia. We used data from a large, 3-year, observational, non-randomized, multisite study of schizophrenia, conducted in the U.S. between 7/1997 and 9/2003. Patients who were initiated on oral atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine, or ziprasidone) or oral typical antipsychotics (low, medium, or high potency) were compared on time to all-cause medication discontinuation for 1 year following initiation. Treatment group comparisons were based on treatment episodes using 3 statistical approaches (Kaplan-Meier survival analysis, Cox Proportional Hazards regression model, and propensity score-adjusted bootstrap resampling methods). To further assess the robustness of the findings, sensitivity analyses were performed, including the use of (a) only 1 medication episode for each patient, the one with which the patient was treated first, and (b) all medication episodes, in...Continue Reading

Associated Clinical Trials

References

Apr 1, 1991·Archives of General Psychiatry·M I HerzJ Vana
May 9, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·J A Cramer, R Rosenheck
Dec 18, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·H A Huskamp
Apr 27, 1999·Medical Care·T W CroghanT J Kniesner
Feb 13, 2001·Biological Psychiatry·G D TollefsonUNKNOWN Lilly Resistant Schizophrenia Study Group
May 29, 2001·Psychiatric Services : a Journal of the American Psychiatric Association·B L SvarstadJ K Sweeney
Jul 4, 2001·Psychopharmacology·K WahlbeckS Leucht
Mar 29, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Patricia ThiedaJohn Kane
Apr 16, 2003·Schizophrenia Bulletin·Kim A WeissJonathan D Huppert
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Nov 12, 2003·Schizophrenia Bulletin·Ramin MojtabaiEvelyn J Bromet
Dec 4, 2003·JAMA : the Journal of the American Medical Association·Robert RosenheckUNKNOWN Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine
Dec 9, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Gerard W K HugenholtzAntoine C G Egberts
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Istvan BitterUNKNOWN Olanzapine HGCK Study Group
Jan 2, 2004·The American Journal of Psychiatry·Dennis S Charney
Jan 15, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·P Joseph GibsonJanet L Ramsey
Feb 11, 2004·The Journal of Nervous and Mental Disease·David S SalkeverPatricia A Russo
Apr 2, 2004·The American Journal of Psychiatry·James E BlackWilliam T Greenough
Aug 5, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Peter J WeidenJulie Locklear
Jan 8, 2005·Psychiatric Services : a Journal of the American Psychiatric Association·Robert A Rosenheck
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators

❮ Previous
Next ❯

Citations

May 11, 2012·European Journal of Clinical Pharmacology·Valentino ContiCorrado Barbui
Oct 20, 2009·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller, Wolfgang Maier
Feb 9, 2012·Schizophrenia Bulletin·Edward Chia-Cheng LaiChia-Yin Lin
Jul 17, 2007·Journal of Clinical Psychopharmacology·Joo Cheol ShimRobert R Conley
Jul 31, 2008·Journal of Psychiatric Practice·Caroline Bonham, Christopher Abbott
Mar 30, 2013·Annual Review of Clinical Psychology·Nina de Lacy, Bryan H King
Oct 6, 2010·BMC Psychiatry·Allen W NyhuisBruce J Kinon
May 29, 2009·Cost Effectiveness and Resource Allocation : C/E·Douglas E FariesHaya Ascher-Svanum
Aug 11, 2012·Patient Preference and Adherence·Louis S MatzaDieter Naber
Feb 22, 2012·Patient Preference and Adherence·William MontgomeryGavan Harrison
Jul 4, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Haya Ascher-SvanumCaroline C Doebbeling
Oct 29, 2008·Current Medical Research and Opinion·Natalie C EdwardsRiad Dirani
Mar 19, 2008·Basic & Clinical Pharmacology & Toxicology·Stig Ejdrup AndersenCharlotte Manniche
Mar 6, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Pierre Thomas
Nov 14, 2007·International Journal of Clinical Practice·M ObradovicM Kos
May 21, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Lei ChenJinhee Park
Jul 28, 2010·Journal of Aging and Health·Alex D FedermanAlbert L Siu
Jul 18, 2017·Organic & Biomolecular Chemistry·Lu ZhangGuanyu Yang
Nov 12, 2010·The Cochrane Database of Systematic Reviews·Claudia Asenjo LobosStefan Leucht
Jan 21, 2011·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Nov 20, 2013·The Cochrane Database of Systematic Reviews·Laila AsmalStefan Leucht
Nov 21, 2007·European Psychiatry : the Journal of the Association of European Psychiatrists·Antonio CiudadInmaculada Gilaberte
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Aug 30, 2019·European Archives of Psychiatry and Clinical Neuroscience·Rebecca SchennachHans-Jürgen Möller
Jan 26, 2011·Epidemiologia e psichiatria sociale·Johanna MeierBernd Puschner

❮ Previous
Next ❯

Software Mentioned

CATIE
SCAP
US

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.